Clinical response and plasma haloperidol levels in schizophrenia
- Cite this article as:
- Mavroidis, M.L., Kanter, D.R., Hirschowitz, J. et al. Psychopharmacology (1983) 81: 354. doi:10.1007/BF00427577
- 30 Downloads
Plasma haloperidol levels were compared to clinical response during the first 14 days of drug treatment in 14 DSM III-diagnosed inpatient schizophrenic patients using an improved methodology, which utilized predetermined constant dosages and derived a therapeutic range of plasma haloperidol levels from a curvilinear regression analysis. An inverted U-shaped relationship was found which reflected a significant curvilinear correlation (r=0.66, P<0.02) between plasma levels (as assayed by gas chromatography) and improvement on the Serial New Haven Schizophrenia Index. A therapeutic window was suggested by the present study, with optimum patient response associated with plasma haloperidol levels of 4.2–11.0 ng/ml for the first 2 weeks of treatment.